Friday, October 2, 2009

Amicus says Gaucher drug misses goal in trial - Forbes


Amicus says Gaucher drug misses goal in trial
Forbes
Amicus shares fell $3.59, or 42 percent, to $4.91 in after-hours trading when the test results were released, following a gain of 17 cents, or 2 percent, ...

and more »
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)